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Summary
The multivariable and progressive natural history of type 2 diabetes limits the effectiveness of available glucose-
lowering drugs. Constraints imposed by comorbidities (notably cardiovascular disease and renal impairment) and the 
need to avoid hypoglycaemia, weight gain, and drug interactions further complicate the treatment process. These 
challenges have prompted the development of new formulations and delivery methods for existing drugs alongside 
research into novel pharmacological entities. Advances in incretin-based therapies include a miniature implantable 
osmotic pump to give continuous delivery of a glucagon-like peptide-1 receptor agonist for 6–12 months and once-
weekly tablets of dipeptidyl peptidase-4 inhibitors. Hybrid molecules that combine the properties of selected incretins 
and other peptides are at early stages of development, and proof of concept has been shown for small non-peptide 
molecules to activate glucagon-like peptide-1 receptors. Additional sodium-glucose co-transporter inhibitors are 
progressing in development as well as possible new insulin-releasing biological agents and small-molecule inhibitors 
of glucagon action. Adiponectin receptor agonists, selective peroxisome proliferator-activated receptor modulators, 
cellular glucocorticoid inhibitors, and analogues of fibroblast growth factor 21 are being considered as potential new 
approaches to glucose lowering. Compounds that can enhance insulin receptor and post-receptor signalling cascades 
or directly promote selected pathways of glucose metabolism have suggested opportunities for future treatments. 
However, pharmacological interventions that are able to restore normal β-cell function and β-cell mass, normalise 
insulin action, and fully correct glucose homoeostasis are a distant vision.
Introduction
A wealth of evidence from prospective and retrospective 
clinical studies supports the premise that early, effective, 
and sustained glycaemic control defers the onset of 
diabetes and reduces the severity of associated 
complications.1–3 However, more than a third of all 
patients with diabetes do not achieve or maintain an 
appropriate glycaemic target.1,4 Although this situation is 
attributed partly to late diagnosis of diabetes, delayed 
introduction or insufficient escalation of treatment, or 
poor patient adherence, more efficacious and durable 
treatments are needed. Type 2 diabetes is usually the 
product of various genetic susceptibilities and 
environmental factors that interact to create a highly 
heterogeneous and progressive pathological changes 
against which existing treatments have substantial 
limitations.5 About half of all patients with type 2 
diabetes require combinations of two or more differently 
acting non-insulin glucose-lowering drugs and about a 
third of patients will require insulin.6 Moreover, the 
complications and comorbidities (eg, cardiovascular 
disease and renal impairment) that typically accompany 
advanced states of insulin resistance and pancreatic 
β-cell dysfunction restrict the choice of available 
treatments.
This update of a previous narrative Review in The Lancet 
in 20117 uses the same literature search procedure to carry 
the review forward to June, 2015. Emphasis is given to 
clinical studies of agents that are advanced in development 
and preclinical experimentation that explores potential 
new therapeutic mechanisms for diabetes. The main sites 
of action of present and possible future glucose-lowering 
treatments are summarised in figure 1 and key features of 
the modes of action of potential future therapies are 
summarised in table 1.8
Pancreatic β-cell function
Overview
Interventions with lasting efficacy are needed to prevent 
and reverse the progressive reduction in pancreatic β-cell 
function and β-cell mass in patients with type 2 diabetes.9 
Compounds acting at the level of the β cell currently 
under investigation include the small molecule insulin 
releasers, glucokinase activators, fatty acid receptor 
agonists, and imeglimin. 
Small molecule insulin releasers
In addition to established initiators of insulin secretion 
(sulfonylureas and meglitinides), many compounds are 
known to improve β-cell function in vitro. These small 
molecule insulin releasers include succinate esters, 
imidazolines, selective phospho diesterase inhibitors, α-2 
adrenergic antagonists, and agents that close Kir6.2 
potassium channels or open membrane calcium 
channels. However, the in-vivo effects of most of these 
compounds are too generalised to specifically target 
β cells and few have progressed in development.10
Glucokinase activators
Activators of the glucose phosphorylating enzyme, 
glucokinase, increase both insulin secretion and hepatic 
glucose metabolism (figure 2). Phase 2 and phase 3 
studies in patients with type 2 diabetes have shown 
modest glucose-lowering for 4–6 months, but efficacy 
quickly reduces thereafter.11 With stimulation of insulin 
secretion at low glucose concentrations, glucokinase 
activators are prone to cause hypoglycaemia. However, 
glucokinase is regulated differently in the liver to the 
β cell, and attention is now focused on the development 
of liver-selective glucokinase activators. Accumulation of 
hepatic triglycerides often occurs during protracted 
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glucokinase activation. This effect might be avoided with 
drugs that also enhance futile cycling in the liver, but 
long-term clinical efficacy remains to be established.12,13
Fatty acid receptor agonists
Several G-protein coupled receptors expressed by 
pancreatic β cells are activated by fatty acids leading to 
enhanced insulin secretion—eg, GPR40 (also known as 
FFAR1) and GPR119. As receptors (not transporters), 
they do not mediate cellular entry of their agonists so 
they do not invoke the detrimental effects of chronic 
excess fatty acids on the metabolism and survival of 
β cells.9 GPR40 agonists increase insulin secretion by 
increasing cytosolic calcium. A promising GPR40 
agonist (TAK-875) was discontinued because of hepatic 
side-effects, but other GPR40 agonists continue in 
development.14
GPR119 agonists activate adenylate cyclase, increasing 
cyclic adenosine monophosphate and potentiating 
nutrient-induced insulin secretion in a similar manner 
to glucagon-like peptide-1 (GLP1).15 Both GPR40 and 
GPR119 are expressed by enteroendocrine pancreatic 
cells and other cells, K cells, L cells, and I cells, and 
synthetic agonists for these receptors can increase the 
secretion of glucose-dependent insulinotropic peptide 
(also known as gastric inhibitory polypeptide, GIP), 
GLP1, peptide YY (PYY), and cholecystokinin, potentially 
enhancing the incretin and satiety effects of these 
hormones. GPR40 and GPR119 receptors are also 
expressed by pancreatic α cells and agonists might 
increase glucagon secretion.16
Another long-chain fatty acid receptor, GPR120 (also 
known as FFAR4), expressed mainly by adipose tissue, 
promotes adipogenesis. Small molecule agonists of this 
receptor improve glucose homoeostasis by increasing 
insulin sensitivity and reducing ectopic fat in preclinical 
studies.17
Imeglimin
Imeglimin is a triazine derivative that enhances glucose-
induced insulin secretion, especially the first phase, and 
improved glycaemic control during phase 2 studies in 
type 2 diabetes. It seems to change cellular energetics, in 
part through closure of mitochondrial permeability 
transition pores, which can also improve peripheral 
insulin sensitivity and reduce hepatic gluconeogenesis.18
Incretin-based therapies
Overview
Hormonal signals from the alimentary tract continue to 
provide important therapeutic templates for type 2 
diabetes. The main incretin hormone, GLP1, has been 
successfully exploited in this respect by changing the 
molecule to avoid rapid inactivation by the enzyme 
dipeptidyl-peptidase-4 (DPP4) or by inhibiting DPP4.4 
GLP1 receptor agonists
Injectable GLP1 receptor agonists (exenatide, liraglutide, 
lixisenatide, albiglutide, and dulaglutide) potentiate 
nutrient-induced insulin release, suppress excess 
glucagon secretion, delay gastric emptying, and exert 
satiety effects that assist with weight control. Although 
these agents have increased β-cell mass in animal 
studies,19 this finding has yet to be clearly shown in 
human beings with type 2 diabetes. To avoid daily or 
weekly injections, a matchstick-sized subcutaneously 
implanted miniature osmotic pump has been developed 
for continuous delivery of up to 80 μg/day of exenatide. 
In an extended phase 2 study, implants delivering doses 
of 40 μg/day or more of this GLP1 receptor agonist for 
48 weeks in patients with type 2 diabetes reduced HbA1c 
(by 0·93–1·42%; 10–15 mmol/mol) from a baseline of 
about 8% (64 mmol/mol) and weight (by 3·0–4·2 kg) 
from a baseline of 93 kg. Initial dose-related nausea 
Available treatments
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production, decrease lipolysis
Thiazolidinediones
Increase insulin sensitivity
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Satiety-inducing agents
Reduce adiposity
Incretin analogue peptides and 
small molecule receptor agonists
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Figure 1: Intervention sites for glucose-lowering, showing available treatments and possible new treatments
GLP1=glucagon-like peptide-1. DPP4=dipeptidyl-peptidase-4. SGLT2=sodium-glucose co-transporter 2 (also 
known as SLC5A2). SGLT1=sodium-glucose co-transporter 1 (also known as SLC5A1). FGF21=fibroblast growth 
factor 21. SPPARM=selective peroxisome proliferator-activated receptor modulator. 11βHSD1=11β-hydroxysteroid 
dehydrogenase 1. *Not indicated for glucose-lowering in all countries. 
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(mostly transient) was reported by about a third of 
participants and antibodies were detected in up to 10% of 
patients but did not seem to impair efficacy of exenatide.20 
This therapy is in phase 3 of development.
Another approach to avoid injections is an oral tablet 
formulation of the GLP1 receptor agonist semaglutide. 
This peptide is in phase 3 trials, including one already 
completed trial (NCT02054897), as a once-weekly 
subcutaneous injection. The oral formulation is 
suggested to be equally effective.21 Studies in mice have 
shown that GLP1 receptor agonists can also be delivered 
by bioencapsulation in chloroplasts.22 Several non-
peptide small molecule GLP1 receptor agonists have 
been characterised in preclinical studies, but clinical 
efficacy has yet to be reported.23
Dipeptidyl-peptidase-4 inhibitors
DPP4 inhibitors (eg, sitagliptin, vildagliptin, saxagliptin, 
linagliptin, and alogliptin) are once-daily (or twice-daily 
for vildagliptin) oral drugs that enhance the effects of 
Mechanism of action Glucose-lowering effect Development 
status
Comments
Glucokinase activators Increase glucokinase activity in 
pancreatic islets and liver
Increase insulin secretion and 
hepatic glucose uptake
Phase 3 Challenges of hypoglycaemia and 
durability
GPR40 (also known as FFAR1) and GPR119 
agonists
Activates fatty acid receptors in 
pancreatic islets and gut
Increase insulin secretion and 
enteroendocrine L-cell incretin 
secretion
Phase 1–3 TAK-875 (GPR40 agonist) discontinued in 
phase 3
Imeglimin Close mitochondrial transition pores Increases insulin secretion and 
decreases gluconeogenesis
Phase 3
Exenatide implantable osmotic pump GLP1 receptor agonist Mimics effects of GLP1 Phase 3 Active for 6–12 months
Oral and subcutaneous semaglutide GLP1 receptor agonist Mimic effects of GLP1 Phase 2–3 Oral drug has similar efficacy to 
subcutaneous injection
Non-peptide GLP1 receptor agonists GLP1 receptor agonist Mimic effects of GLP1 Preclinical Proof of concept
Omarigliptin (once-weekly) DPP4 inhibitor Increase endogenous incretin 
action
Phase 3 Efficacy similar to sitagliptin
TGR5 (also known as GPBAR1) agonists Stimulate bile acid receptors in ileum Increase L-cell incretin secretion Preclinical Preliminary observations
Fixed-ratio combinations; GLP1 receptor agonists 
with insulin
GLP1 receptor agonist and basal insulin Mimic effects of GLP1 and 
insulin at same time
Phase 3 Insulin degludec and liraglutide 
combination was recently approved and 
insulin glargine and lixisenatide 
combination is in development
Hybrid and chimeric designer peptides Agonism or partial antagonism of 
selected peptides
Mimic effects of selected 
incretins and other peptides
Preclinical Proof of concept
Glucagon receptor antagonists Decrease glucagon action Decrease hepatic glucose output Preclinical to 
phase 2
Several drugs identified in preclinical 
studies, restricted clinical progression
Insulin receptor signalling potentiators Prolong Tyr phosphorylation of insulin 
receptor B-subunit
Increase insulin action Preclinical Proof of concept—eg, PTP1B (also known 
as PTPN1) inhibitors and vanadium salts
SGLT1 and 2 inhibitors Selectively decrease SGLT1 (also known 
as SLC5A1) and SGLT2 (also known as 
SLC5A2) activity in gut and kidney
Increase renal glucose 
elimination; delays gut glucose 
absorption; changes incretin 
secretion
Phase 2–3 Efficacy shown in initial clinical studies
Non-peptide adiponectin receptor agonists Adiponectin R1/R2 agonists Increase insulin action Preclinical Proof of concept
FGF21 analogues FGF21 receptor agonists Increase insulin sensitivity and 
improves lipid profile
Phase 1 Might act partly through adiponectin
GPR120 (also known as FFAR4) Activates fatty acid receptors in 
adipose and other tissues
Increases insulin sensitivity and 
adipogenesis
Preclinical Proof of concept
Selective peroxisome proliferator-activated 
receptor modulators
Selective peroxisome proliferator-
activated receptor alpha, gamma, and 
delta agonists
Increase insulin sensitivity, 
adipogenesis or lipid profile, and 
islet β-cell viability
Phase 1–2 Opportunity to selectively enhance efficacy 
and reduce unwanted effects
11β hydroxysteroid dehydrogenase-1 inhibitors Inhibit 11β hydroxysteroid 
dehydrogenase-1 conversion of 
cortisone to cortisol in liver and 
adipose tissue
Increase insulin sensitivity and 
improves lipid profile
Phase 1–2 Challenge to prevent compensatory rise in 
concentration of adrenocorticotropic 
hormone
Fructose-1,6 bisphosphatase inhibitors Increase fructose-1,6 bisphosphatase 
activity
Decrease hepatic glucose output Phase 2 Initial clinical studies show efficacy
Adenosine monophosphate kinase activators Increase adenosine monophosphate 
kinase cellular effects on nutrient 
metabolism
Increase glucose uptake and 
metabolism
Preclinical Proof of concept
This list is not comprehensive but shows the various mechanisms and stages of development represented in this Review.
Table 1: List of some potential new glucose-lowering medications for type 2 diabetes
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endogenous incretins by prolonging their circulating 
half-lives. Because the side-effects of these drugs have 
been minimal to-date, long-acting DPP4 inhibitors have 
been investigated.24 In the most advanced stage of 
development, omarigliptin has shown similar efficacy 
and tolerability as sitagliptin in phase 3 clinical studies.25
TGR5 agonists
The bile acid sequestrant colesevelam, which is indicated 
for use as a glucose-lowering drug in some countries, 
raises the possibility that carriage of bile acids more 
distally along the ileum could activate the TGR5 (also 
known as GPBAR1) bile acid receptors on L cells and 
enhance GLP1 secretion. Preliminary studies are 
investigating whether poorly absorbed TGR5 agonists 
can act distally along the intestinal tract to enhance GLP1 
secretion.26
Peptide combinations
A mix of two differently acting peptides in the same 
injection became a therapeutic reality with the 
introduction of IDegLira, a fixed-ratio combination of 
liraglutide with insulin degludec (ratio of 1·8 mg of 
liraglutide to 50 units of insulin degludec). This 
combination is titrated in a similar manner to insulin, 
and during a 1-year prospective randomised phase 3 
trial27 in patients who had insulin-naive type 2 diabetes, 
once-daily subcutaneous injection of IDegLira reduced 
HbA1c by 1·84% (20·2 mmol/mol) compared with 1·40% 
(15·3 mmol/mol) for insulin degludec alone and 1·21% 
(13·2 mmol/mol) for liraglutide alone (each p<0·0001 
versus IDegLira). The combination achieved this effect 
with a lower insulin dose (39 units) than insulin degludec 
alone (62 units; p<0·0001), and avoided weight gain in 
patients (p<0·0001 between each treatment group). 
Preliminary data from a phase 2 study indicate that a 
fixed-ratio combination of lixisenatide and insulin 
glargine (Lixilan: ratio 50 μg of lixisenatide to 100 units of 
glargine) has similar efficacy in patients who had insulin-
naive type 2 diabetes.28
Preclinical and clinical studies have also explored the 
use of hybrid peptides in which two or more peptides are 
linked together to form a single molecule.29 These hybrids 
have mostly included combinations of GLP1 with 
glucagon, GIP, or other intestinal peptides.30 Hybrid 
molecules provide an opportunity to combine the effects 
of various peptides that affect blood glucose, lipids, 
satiety, energy expenditure, and adiposity, such as 
incretins, glucagon receptor agonists or antagonists, 
oxyntomodulin, PYY, obestatin, and ghrelin antagonists. 
These agents can be customised with a selection of 
desired sequences to construct chimeric molecules that 
exploit particular epitopes and enable new therapeutic 
portfolios in a single molecule.31,32 For example, molecules 
with satiety-inducing, weight-lowering, and glucose-
lowering properties might reproduce the metabolic 
effects of bariatric surgery.7 Although substantial 
physicochemical constraints and potential immunological 
issues need to be addressed, multipurpose designer 
molecules offer a novel potential therapeutic prospect.
Glucagon secretion and action
Reduction of prandial (but not fasting) glucagon 
secretion by pancreatic α cells is an important action of 
GLP1 receptor agonists. Other inhibitors of glucagon 
secretion (eg, somatostatin analogues) have not been 
suitable for glucose-lowering in type 2 diabetes, mainly 
because of interference with the counter-regulatory 
response to hypoglycaemia, which is already defective in 
most patients.10
Despite many accounts in the medical literature of 
glucagon receptor antagonists over more than 20 years,33 
few have progressed beyond initial clinical trials.34,35 
Unwanted effects on liver function have been described 
with some glucagon receptor antagonists, and glucagon 
receptor antagonism could possibly cause compensatory 
hyperglucagonaemia and rebound hyperglycaemia if 
treatment is not maintained.
Insulin action
Insulin binds to the extracellular α subunits of the 
insulin receptor, changing their conformation. This 
effect in turn changes conformation of the β subunits 
Figure 2: Pancreatic β cell showing cellular mechanisms of insulin-releasing drugs8
Blue boxes=approved drugs. Pink boxes=drugs under investigation. ATP=adenosine triphosphate. cAMP=cyclic 
adenosine monophosphate. GLUT=glucose transporter isoform. GLP1=glucagon-like peptide-1. GPR40=G-
protein-coupled receptor 40 (also known as FFAR1). GPR119=G-protein-coupled receptor 119. IP3=inositol 
trisphosphate. PLC=phospholipase C. KATP=ATP-sensitive potassium channel. Kir=inwardly rectifying potassium 
channel. PKA=protein kinase A. PKC=protein kinase C. SUR=sulfonylurea receptor. 
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that extend into the cytosol, exposing tyrosine residues in 
the β subunits. Phosphorylation of these residues 
enables the β subunits to act as kinase enzymes, 
activating insulin receptor substrate (IRS) proteins that 
trigger the various post-receptor pathways responsible 
for the genomic and non-genomic actions of insulin. 
Thus, insulin resistance in patients with type 2 diabetes 
has many potential causes, many different presentations, 
and many possible sites for intervention (figure 3).5,7–9 
However, the rate-limiting defect is almost never 
identified and the potential benefits gained by 
circumventing any one defect might be off set by 
disturbances elsewhere in the insulin-receptor—effector 
pathways. Moreover, the various post-receptor signalling 
pathways of insulin action interact with, and are partly 
shared by, many other cellular signalling pathways, 
creating a challenge for any therapeutic intervention to 
act selectively on insulin action without interfering with 
other cellular control processes. In view of these 
constraints, much research into insulin resistance has, 
unsurprisingly, not yet yielded a new drug.
Because of the complexity of insulin receptor binding,36 
small (non-peptide) molecules are unlikely to be able to 
duplicate this act. However, a monoclonal antibody 
(XmetA) that exhibits high affinity binding to the insulin 
receptor at a different site to insulin initiated some of the 
effects of insulin in animal cells in vitro and improved 
glycaemic control in insulin resistant diabetic mice.37 
This finding suggests that conformational changes to the 
α subunit of the insulin receptor that differ from those 
induced by insulin binding could be exploited to produce 
conformational changes in the β subunit that will elicit 
therapeutically beneficial effects.
A fungal metabolite, demethylasterriquinone, which 
interacts directly with the cytosolic part of the insulin 
receptor β subunit, can initiate IRS-1-mediated post-
receptor pathways without needing insulin binding. 
Although demethylasterriquinone is not suited to clinical 
development, the metabolite’s ability to control the 
hyperglycaemia in diabetic animals suggests an 
opportunity exists for small molecules to mimic the 
actions of insulin.38
Various drugs have been reported to potentiate insulin-
initiated tyrosine phosphorylation of the insulin receptor 
β subunit, or prevent its tyrosine dephosphorylation by 
phosphatases.39 In particular, drugs directed against 
protein tyrosine phosphatase 1B and more general 
phosphatase inhibitors, such as vanadium salts, have 
successfully treated hyperglycaemic animals and shown 
efficacy in clinical trials, but none has proved sufficiently 
selective or free of side-effects to proceed into routine 
clinical use.40,41
Several intermediates within or activated by the post-
receptor insulin signalling pathways exert a negative 
feedback by phosphorylating serine residues on the 
β subunit and IRS proteins (eg, protein kinase C-theta 
and the mammalian target of rapamycin). Attempts to 
interrupt this feedback have not been sufficiently 
selective. Provision of substrates for individual steps in 
the post-receptor pathways (eg, administration of the 
chiroinositol analogue pinitol enables signalling through 
phosphatidylinositol 3-kinase) is another approach under 
investigation.10
Sodium–glucose co-transporter inhibitors
Inhibitors of sodium–glucose co-transporters (eg, 
canagliflozin, dapagliflozin, and empagliflozin) are 
mainly directed against SGLT2 (also known as SLC5A2), 
which is located in the initial part of the proximal tubules 
and is responsible for reabsorption of about 90% of 
filtered glucose. Inhibition of SGLT2 causes excess 
glucose to be eliminated in the urine, which enables 
insulin-independent lowering of glucose, and lowering of 
bodyweight and blood pressure.42 Several further SGLT2-
selective inhibitors are advanced in development, all 
offering similar efficacy in clinical trials.43
Sotagliflozin strongly inhibits both SGLT2 and SGLT1 
(also known as SLC5A1) and has also shown similar 
Figure 3: Pathways of intracellular insulin signalling showing some of the potential sites for therapeutic 
intervention7,8
Dotted lines=inhibition. Solid lines=activation. Some agents listed in this figure are not discussed in this up-date 
and the reader is referred to references 7 and 8. AKT=protein kinase B. AMPK=adenosine monophosphate-activated 
protein kinase. eNOS=endothelial nitric oxide synthase. FOXO1=forkhead box protein O1A. GLUT=glucose transporter 
isoform. GRB=growth factor receptor binding protein. GSK3=glycogen synthase kinase 3. IKBKB=inhibitor kappa-B 
kinase-β. IRS=insulin receptor substrate. JNK=c-Jun N-terminal kinase. MAPK=mitogen-activated protein kinase. 
MEK=mitogen-activated protein kinase kinase. mTOR=mammalian target of rapamycin. PC-1=glycoprotein-1. 
PDK=phosphoinositide-dependent protein kinase. PGC-1α=PPAR co-activator-1α (also known as PPARGC1A). 
PI3K=phosphatidylinositol 3-kinase. PIP2=phosphatidylinositol-3,4-bisphosphate. PIP3=phosphatidylinositol-3,4,5-
trisphosphate. PKC=protein kinase C. PPAR=peroxisome proliferator-activated receptor. PP2C=protein phosphatase 
2C. PTEN=phosphatase and tensin homologue. PTP-1B=protein tyrosine phosphatase-1B (also known as PTPN1). 
RAF=a serine–threonine protein kinase. RAS=a guanosine triphosphatase. ROS=reactive oxygen species. RXR=retinoid 
X receptor. SHIP-2=src homology-2-inositol phosphatase (also known as INPPL1). SOCS3=suppressor of cytokine 
signalling 3. SOS=SOS Ras/Rac guanine nucleotide exchange factor. STAT5B=signal transducer and activator of 
transcription 5B. TNFα=tumour necrosis factor α.
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efficacy to other SGLT2 inhibitors in initial clinical 
studies.44 SGLT1 mediates glucose absorption from the 
small intestine and contributes to the reabsorption of 
about 10% of filtered glucose by the kidney. 
Pharmacokinetic properties of this dual SGLT inhibitor 
suggest that it can defer intestinal glucose absorption 
more distally without causing malabsorption and might 
also increase the glucosuric effect. Sotagliflozin is now in 
phase 3 trials.45 SGLT inhibitors that mainly inhibit 
SGLT1 are  under investigation in phase 1.46
Adipokine-based treatments
In addition to facilitating weight loss through centrally 
mediated satiety and thermogenic effects, leptin exerts 
direct peripheral effects to improve insulin action and 
suppress glucagon. However, the glucose-lowering 
efficacy of leptin and leptin analogues was nominal 
during phase 3 trials in obese patients with type 2 
diabetes, and benefits might only occur in individuals 
who are severely leptin deficient.47
Concentrations of another adipocyte hormone, 
adiponectin, are typically low in patients with type 2 
diabetes, especially in the overweight, and adiponectin is 
known to exert several potentially beneficial effects 
including improved insulin sensitivity, improved 
endothelial function, and an anti-inflammatory effect.48,49  
Orally active small-molecule agonists of the adiponectin 
receptors, ADIPOR1 and ADIPOR2, have been shown to 
improve glycaemic control and prolong lifespan in 
insulin resistant diabetic animals, raising expectations 
for clinical studies.48,49
Preliminary data suggest that other treatments based on 
adipocyte hormones could be applied to type 2 diabetes. 
For example, resistin reduces insulin sensitivity, increases 
proinflammatory cytokines, and adversely affects vascular 
function, whereas immunoneutralisation of resistin has 
improved insulin sensitivity in rodents.50 Increased 
concentrations of the retinol-binding protein 4 (RBP4), 
which transports plasma retinoids, have been detected 
early in the development of insulin resistance, and 
interventions that reduce RBP4 have increased insulin 
sensitivity in animals.51
Fibroblast growth factor 21 (FGF21) is a peptide 
secreted by adipose tissue, liver, and muscle, which 
promotes fatty acid oxidation and hepatic gluconeogenesis 
during starvation. Plasma concentrations of FGF21 are 
raised in obesity and type 2 diabetes, possibly due to 
FGF21 resistance, and preliminary animal and human 
studies suggest that administration of FGF21 analogues 
can improve the lipid profile, reduce insulin resistance, 
and assist glucose-lowering, partly through increased 
production of adiponectin.52,53
Selective peroxisome proliferator-activated 
receptor modulators
The nuclear peroxisome proliferator-activated receptor 
(PPAR) family offers a selection of potentially beneficial 
therapeutic effects but accompanying side-effects need to 
be minimised. PPARγ improves insulin sensitivity, 
glycaemic control, and various markers of vascular health 
while reducing inflammation, but also increases fluid 
retention and risk of heart failure, reduces bone mineral 
density, and often causes excessive adipogenesis.54 PPARα 
improves the lipid profile, reduces inflammation, and 
seems to benefit microvascular complications, but might 
raise creatinine and risk of myopathological 
abnormalities,54 whereas PPARδ counters weight gain 
through increased thermogenic energy expenditure, but 
long-term safety in man is not established.54 Agents that 
selectively activate PPARγ and PPARα (dual PPARα/γ 
agonists, or glitazars), and triple PPAR agonists that also 
activate PPARδ (known as panPPARs) have not been 
introduced for routine clinical use due to side-effects.54 
Attention is directed to more selective PPAR modulators 
(SPPARMs) designed to capture desired effects and 
minimise unwanted effects.55 For example, addition of a 
nonthiazolidinedione SPPARM, INT131, showed similar 
glucose-lowering efficacy to pioglitazone but with less 
oedema and less weight gain during a phase 2A, 24-week 
randomised double-blind study56 in patients with type 2 
diabetes receiving a sulfonylurea with or without 
metformin.
Inhibitors of 11β-hydroxysteroid 
dehydrogenase 1
Inhibitors of 11β-hydroxysteroid dehydrogenase 1 
(11βHSD1) reduce the production of active cortisol from 
cortisone.57 Such an inhibitor, INCB13739, improved 
insulin sensitivity, reduced HbA1c by 0·6% (6 mmol/
mol), improved the lipid profile and reduced bodyweight 
during a 12-week randomised phase 2 double blind 
placebo controlled study58 in metformin-treated type 2 
diabetes subjects. However, the efficacy achieved with 
11βHSD1 inhibitors has been low and although these 
agents should theoretically restrict cortisol production 
within the liver and adipose tissue, a reduction of 
circulating cortisol can occur and cause a compensatory 
increase in adreno corticotropic hormone.59
Agents that directly affect glucose production 
or metabolism
Many compounds have been shown to reduce blood 
glucose in diabetic animals by suppressing hepatic 
glucose production, but few have progressed in clinical 
development.60 High risk of hypoglycaemia has been a 
limitation as noted with glucose-6-phosphatase 
inhibitors,60 because these agents inhibit the last step in 
gluconeogenesis and glycogenolysis. The risk of 
hypoglycaemia might be lessened with inhibitors of 
fructose-1,6 bisphosphatase, which create a compensatory 
increase in glycogenolysis, and some phase 2 clinical 
studies are in progress.61
Activation of adenosine monophosphate-activated 
protein kinase (AMPK), which is one of the cellular 
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mechanisms of metformin and adiponectin, reduces blood 
glucose by increasing peripheral glucose uptake and 
increasing the metabolism of glucose and fatty acids. AMP 
is the main cellular activator of AMPK, and analogues of 
AMP are being explored as potential treatments.62
Epigenetics, genetics, and proteomics
The epigenetic approach is shown by sirtuins, which are 
nicotinamide-adenine-dinucleotide-dependent deacety-
lases and ADP ribosyltransferases that change gene 
transcription through chromatin silencing. Several 
small molecule sirtuin activators have produced effects 
similar to chronic caloric restriction in animal models. 
These effects include mitochondrial biogenesis and 
thermogenesis, glucose lowering, and improved 
vascular function, prompting continuing investigations 
into potential applications to treat obesity, diabetes, and 
cardiovascular disease.63,64
Genetic and proteomic studies continue to inform on 
the multivariable causes and pathogenesis of type 2 
diabetes and identify specific treatment targets for a few 
patients, but for most patients these approaches have yet 
to inform the design of new drugs.65–67
Antiobesity drugs
Drugs approved for weight loss can assist glycaemic 
control in overweight and obese patients with type 2 
diabetes. These products include the established intestinal 
lipase inhibitor orlistat and several newly approved satiety-
inducing drugs, notably a high dose GLP1 receptor agonist 
(liraglutide), a 5HT2c serotonin receptor agonist 
(lorcaserin), a phentermine-topiramate combination, and 
a bupropion-naltrexone combination.68–70 Further potential 
weight-lowering drugs, mostly based on intestinal satiety 
hormones, are in early development.70
Insulins
Advances in insulin treatment for patients with type 2 
diabetes are beyond the remit of this Review, and have 
been reviewed recently.71 Key developments for the 
immediate future include biosimilar insulins, notably 
biosimilar glargine and lispro, and the introduction of 
more concentrated U200–U500 formulations of existing 
insulins. Clinical assessment of an ultra-fast short-acting 
formulation of insulin aspart and a long-acting 
formulation of lispro are advancing in development. An 
inhaled insulin (afrezza) has received little use since its 
launch in the USA in 2015: a buccal spray insulin is now 
available in some countries, and closed-circuit insulin-
glucagon pumps and other artificial pancreas devices are 
advancing in development. Delivery of insulin through 
skin patches or oral insulin formulations continue to be 
developed, and so-called smart insulins, which are 
activated or released from subcutaneous or circulating 
depots or skin patches in response to rising glucose 
concentrations, are giving encouraging results in 
preclinical studies.72
Safety issues
Safety is particularly relevant yet difficult to assess for 
glucose-lowering treatments in view of their long-term 
use in patients with comorbidities.73 Cardiovascular risk 
is substantially raised in patients with type 2 diabetes 
and the US Food and Drug Administration (FDA) 
requires a meta-analysis of all cardiovascular events in 
phase 2 and 3 trials as part of any application for a new 
glucose-lowering treatment.74,75 The FDA has also 
requested or encouraged extensive post-marketing 
randomised controlled cardiovascular safety studies 
with composite endpoints that include cardiovascular 
deaths and non-fatal myocardial infarction and stroke 
(table 2). The studies completed so far with saxagliptin 
(SAVOR-TIMI),76 alogliptin (EXAMINE),77 sitagliptin 
(TECOS),78 and lixisenatide (ELIXA)79 have reassuringly 
confirmed no adverse composite cardiovascular 
outcomes, and empagliflozin (EMPA-REG)80 has 
reported a significant 14% reduction in its composite 
cardiovascular outcome.80 During these studies other 
safety issues were being monitored including acute 
pancreatitis, bone fractures, infections, and cancers, 
and no significant increases in these adverse events 
have been reported to date. Although future drugs will 
ideally give positive outcomes in long-term 
cardiovascular safety trials, outcomes will vary with the 
numbers of different cardiovascular diseases, the 
duration of the study, and other variables across the 
different trial populations studied. Thus, the question 
arises as to whether heavy investment into large post-
marketing cardiovascular outcome studies for new 
diabetes drugs could be compromising endeavours in 
innovative research.
Drug Start 
date
End date Mean or 
median 
duration 
(years)
n Primary 
endpoint
EXAMINE* Alogliptin 2009 2014 1·5 5380 3-pt MACE
SAVOR- TIMI 53* Saxagliptin 2010 2014 2·1 16 492 3-pt MACE
TECOS* Sitagliptin 2008 2015 2·8 14 671 4-pt MACE
ELIXA* Lixisenatide 2010 2015 ~4·0 6075 4-pt MACE
EMPA-REG* Empagliflozin 2010 2015 3·1 7020 3-pt MACE
LEADER Liraglutide 2010 2016 ~5·0 9340 3-pt MACE
CANVAS Canagliflozin 2009 2017 ~4·0 4407 3-pt MACE
EXSCEL Exenatide QW 2010 2018 ~5·5 14 000 3-pt MACE
CAROLINA Linagliptin 2010 2018 ~8·0 6000 4-pt MACE
CARMELINA Linagliptin 2013 2018 ~4·0 8300 4-pt MACE
DECLARE-TIMI 58 Dapagliflozin 2013 2019 ~6·0 17 150 3-pt MACE
REWIND Dulaglutide 2011 2019 ~6·5 ~9600 3-pt MACE
ACE Acarbose 2009 ? ~4·0 ~700 3-pt MACE
MACE=major adverse cardiovascular event. 3 point MACE=composite of cardiovascular death and non-fatal 
myocardial infarction and stroke. 4 point MACE=3 point MACE plus hospitalisation for another specified cardiovascular 
event (eg, angina, heart failure). *Studies for which results have already been reported.
Table 2: Post-marketing randomised cardiovascular safety studies for glucose-lowering drugs
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Conclusion
Glycaemic control is crucial to the successful management 
of type 2 diabetes, but despite the variety of differently 
acting glucose-lowering drugs available, reversing the 
disease process and reinstatement of normal glucose 
homoeostasis is rarely possible. The need for multiple 
treatments has given rise to many new fixed-dose 
combinations of existing agents and further fixed-dose 
combinations are envisaged.81 Innovative approaches with 
preclinical proof of concept include fatty acid receptor 
agonists and other novel interventions to promote β-cell 
function, chimeric designer peptides with pancreatic, 
satiety and thermogenic effects, small molecules to 
activate GLP1 receptors and potentiate insulin receptor 
β-subunit signalling, adipokine-based agents such as 
adiponectin receptor agonists, and AMPK activators. 
Many compounds have progressed into clinical studies 
and an analysis of ClinicalTrials.gov in February, 2014, has 
identified 180 trials registered for drugs to treat diabetes 
and its complications.82 However, most of the drugs that 
are advanced in development are different formulations of 
existing drugs or new members of existing classes with 
modest pharmacokinetic modifications. Entirely new 
interventions to address the underlying aetiopathogenic 
lesions of type 2 diabetes remain elusive.
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